Novartis' Exjade Goes To Blood Products Committee Sept. 29
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee likely to discuss iron chelator’s failure to show non-inferiority to existing treatment in 1,000-patient clinical program.